Compare Booz Allen Hamilton Holding Corporation (BAH) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Booz Allen Hamilton Holding Corporation vs Cassava Sciences Inc — how do they compare? Booz Allen Hamilton Holding Corporation trades at $76.99 (market cap $9.45B), while Cassava Sciences Inc trades at $0.94 (market cap $47.75M). The key difference: Booz Allen Hamilton Holding Corporation is far larger — about 197.9× Cassava Sciences Inc's market cap, and Booz Allen Hamilton Holding Corporation pays a 3% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| BAH | FLNA | |
|---|---|---|
Market Cap | $9.45B | $47.75M |
Sector | Industrials | Health |
52-Week High | $111.63 | $4.64 |
52-Week Low | $59.71 | $0.87 |
Enterprise Value | $13.07B | -$34.93M |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Booz Allen Hamilton (BAH) trades at $77.9, up 2.43% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with a 7.01% net margin and 68.11% ROE, supported by $11.98B revenue in 2025. Analysts maintain a Buy consensus with a $84.67 price target, citing government contracts and AI investments as growth drivers, though debt levels and civil revenue weakness pose concerns.
The outlook for BAH is positive due to consistent earnings outperformance and strategic focus on national security and cybersecurity. Investment appeal lies in its discounted valuation (P/E 12.33) and dividend yield, but risks include high leverage (debt-to-asset 54.67%) and reliance on government spending, which could impact growth if budget pressures arise.
FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.
The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
Read more on BAH →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
